» Articles » PMID: 21385946

MicroRNA in Central Nervous System Trauma and Degenerative Disorders

Overview
Date 2011 Mar 10
PMID 21385946
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) are a novel class of small noncoding RNAs that negatively regulate gene expression at the posttranscriptional level by binding to the 3'-untranslated region of target mRNAs leading to their translational inhibition or sometimes degradation. MiRNAs are predicted to control the activity of at least 20-30% of human protein-coding genes. Recent studies have demonstrated that miRNAs are highly expressed in the central nervous system (CNS) including the brain and spinal cord. Although we are currently in the initial stages of understanding how this novel class of gene regulators is involved in neurological biological functions, a growing body of exciting evidence suggests that miRNAs are important regulators of diverse biological processes such as cell differentiation, growth, proliferation, and apoptosis. Moreover, miRNAs are key modulators of both CNS development and plasticity. Some miRNAs have been implicated in several neurological disorders such as traumatic CNS injuries and neurodegenerative diseases. Recently, several studies suggested the possibility of miRNA involvement in neurodegeneration. Identifying the roles of miRNAs and their target genes and signaling pathways in neurological disorders will be critical for future research. miRNAs may represent a new layer of regulators for neurobiology and a novel class of therapeutic targets for neurological diseases.

Citing Articles

Sex-Biased Expression and Response of microRNAs in Neurological Diseases and Neurotrauma.

Geleta U, Prajapati P, Bachstetter A, Nelson P, Wang W Int J Mol Sci. 2024; 25(5).

PMID: 38473893 PMC: 10931569. DOI: 10.3390/ijms25052648.


High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.

Mikulski D, Nowicki M, Drozdz I, Misiewicz M, Koscielny K, Okonski K Front Oncol. 2023; 13:1250355.

PMID: 37829335 PMC: 10565214. DOI: 10.3389/fonc.2023.1250355.


MicroRNA Profiles in Critically Ill Patients.

Alikiaii B, Bagherniya M, Askari G, Rajendram R, Sahebkar A Curr Med Chem. 2023; 31(41):6801-6825.

PMID: 37496239 DOI: 10.2174/0929867331666230726095222.


Identification of Key Target Genes and Pathway Analysis in Nonalcoholic Fatty Liver Disease Via Integrated Bioinformatics Analysis.

Chen X, Zhang L, Wang Y, Li R, Yang M, Gao L Balkan J Med Genet. 2023; 25(1):25-34.

PMID: 36880036 PMC: 9985361. DOI: 10.2478/bjmg-2022-0006.


Brain-enriched miR-128: Reduced in exosomes from Parkinson's patient plasma, improves synaptic integrity, and prevents 6-OHDA mediated neuronal apoptosis.

Bhattacharyya P, Biswas A, Biswas S Front Cell Neurosci. 2023; 16:1037903.

PMID: 36713778 PMC: 9879011. DOI: 10.3389/fncel.2022.1037903.


References
1.
Nakanishi K, Nakasa T, Tanaka N, Ishikawa M, Yamada K, Yamasaki K . Responses of microRNAs 124a and 223 following spinal cord injury in mice. Spinal Cord. 2009; 48(3):192-6. DOI: 10.1038/sc.2009.89. View

2.
Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L . The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008; 14(11):1271-7. DOI: 10.1038/nm.1880. View

3.
Chan C, Elemento O, Tavazoie S . Revealing posttranscriptional regulatory elements through network-level conservation. PLoS Comput Biol. 2005; 1(7):e69. PMC: 1309705. DOI: 10.1371/journal.pcbi.0010069. View

4.
Esau C, Monia B . Therapeutic potential for microRNAs. Adv Drug Deliv Rev. 2007; 59(2-3):101-14. DOI: 10.1016/j.addr.2007.03.007. View

5.
Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View